LCS_-_2of2

Introduction

  • Discussing incidental findings focusing on lung cancer screening.

  • The topic is controversial and requires further discussion.

Understanding Incidental Findings

  • Definition: Incidental findings are less important occurrences that are discovered unintentionally while assessing something else, e.g., lung cancer screening.

  • Debatable nature: Opinions vary widely on what incidental findings should be reported.

  • Audience poll indicates varied responses on reporting findings, showing many perspectives exist.

Differentiating Screening from Diagnostic Imaging

  • Radiologists differentiate between diagnostic imaging and screening:

    • Diagnostic imaging: Aimed at individual health outcomes.

    • Screening: Focuses on population health to improve general community health and reduce disease burden.

  • Acknowledgement that screening tests are not diagnostic; they aim to classify persons who likely have a disease versus those who likely do not.

Types of Incidental Findings

  • Incidental lesions: Non-nodular abnormalities that could indicate malignancies (e.g., renal lesions, adenopathies).

  • Challenges arise due to varied definitions (e.g., clinically relevant, actionable) and lack of standardization.

Two Groups of Incidental Findings

  1. Incidental Lesions: Potentially serious abnormalities that could significantly benefit reporting due to ethical considerations.

    • Examples include lesions in kidneys, liver, and thyroid.

  2. Opportunistic Findings: Abnormalities that could also be used for screening other diseases (e.g., coronary artery calcifications, emphysema).

    • Reporting these could reduce overall morbidity and mortality.

Current Context and Challenges

  • Prevalence of Incidental Findings: Very common in lung cancer screenings, with significant findings reported in approximately 1/3 of participants in trials.

  • The challenge of characterizing findings due to factors like low-dose CT noise.

  • High requirement for additional testing can lead to participant anxiety and financial impact on healthcare systems.

Implications of Reporting Incidental Findings

  • Majority of referred participants often experience additional tests leading to more findings, not always cancer-related.

  • There is significant patient anxiety associated with incidental findings and follow-up evaluations.

  • Economic impact includes additional costs for follow-ups and testing, with varying data on total costs and effectiveness.

Evidence from Lung Cancer Screening Trials

  • Studies (e.g., NLST, Nelson trial) show low rates of malignant findings related to incidental lesions, with very few cancers detected.

  • Evidence suggests that routine reporting of incidental findings may not always lead to clinically relevant outcomes.

  • The consensus leans towards a lack of necessity for systematic reporting of findings that are unlikely to benefit the patient.

The Debate: Reporting on Emphysema and Coronary Artery Calcifications

  • Emphysema: Associated with COPD, shows impact on survival and lung cancer risk, making it valuable to report in screening.

  • Cardiovascular Risks: High prevalence in screened populations and easy identification via CT, urging the importance of discussing reporting practices.

Guidelines and Recommendations

  • Current guidelines from various organizations present differing views on what findings to report.

  • Concerns exist about the practicality of reporting every abnormality noted on scans, advocating for a measured, evidence-based approach.

  • Final recommendations emphasize the need for clear guidelines and a focus on implementing findings that have proven benefit in patient outcomes.

Conclusion

  • Distinction between screening and diagnostic radiology is critical.

  • Emphasis on potential benefits of screening for conditions like cardiovascular diseases and COPD is vital, but reporting criteria need to be carefully set.

  • Future studies and data on cost-effectiveness for additional reported findings are necessary.

  • Role of Artificial Intelligence (AI) in evaluating incidental findings in the future is acknowledged.